Lorcaserin treatment decreases body weight and improves cardiometabolic risk factors of obese adults: A 6-month-long, randomized, placebo-controlled, double-blind clinical trial.

Lorcaserin is a serotonin 2c receptor agonist, which promotes weight loss while improving type 2 diabetes and atherogenic lipid profile without higher rates of major cardiovascular events. The full spectrum of the possible lorcaserin-induced cardiometabolic improvements remains to be clarified. Thus...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes Obes Metab
Main Authors: Tuccinardi, Dario, Farr, Olivia M., Upadhyay, Jagriti, Oussaada, Sabrina M., Mathew, Hannah, Paschou, Stavroula A., Perakakis, Nikolaos, Koniaris, Anastasia, Kelesidis, Theodoros, Mantzoros, Christos S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6504613/
https://ncbi.nlm.nih.gov/pubmed/30724455
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13655
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados